Skip to main content
Premium Trial:

Request an Annual Quote

Millipore to Buy Serologicals for $1.4B in Cash; Firm Hopes to Pursue New Markets, Grow Eurasian Sales

NEW YORK (GenomeWeb News) - Millipore will acquire Serologicals for $1.4 billion in cash --- which is how much revenue the combined comany will likely generate this year, the firms said today.
 
The acquisition will enable Millipore's Bioscience Division, which includes tools for protein and DNA research, analytical samples preparation, and bioassay development, to play in the drug-discovery products and services, antibodies, cell biology reagents, and stem cell research markets.
 
Millipore's Bioprocess Division, meantime, will gain Serologicals' cell culture supplements, which will help it to enter the upstream bioprocessing market, which it pegs at $1 billion. Combined, these products will enable Millipore to sell upstream cell culture and downstream separation offerings for biopharmaceutical production.
 
"With the addition of Serologicals' R&D capabilities, we will ... be able to pursue new markets and bring together the applications expertise of both companies," Millipore Chairman, President, and CEO of Martin Madaus said in a statement.
 
Millipore also said it expects to increase sales of Serologicals' products in international markets such as Europe, Asia and Japan, where Millipore has a significant presence.
 
Millipore said the buy will enable it to generate around $1.4 billion in combined 2006 and grow 2007 receipts by between 9 and 11 percent year over year. Serologicals generated $274.9 million in revenue last year, a 40.3-percent increase over 2004.
 
The combined company, which will employ around 5,800 people, will "have significantly expanded" R&D capabilities and a worldwide sales, sales support, and service organization.
 
The acquisition is expected to close by June 30.
 
Terms of the deal, which is subject to Serologicals shareholder approval, customary regulatory approvals, and other conditions, call for Serologicals shareholders to receive $31.55 in cash for each common share they own.
 
The acquisition will enable Millipore to "optimize workflows from sample preparation, to developing and performing assays, to analyzing results," Madaus said. "Our ... offering will include process development and scale-up, upstream processing, downstream filtration, and ongoing compliance monitoring and testing."
 
It was not immediately clear whether the acquisition will cause Millipore to shed Serologicals staff, but Madaus said "we welcome the employees of Serologicals to Millipore."

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.